Back to News
Market Impact: 0.45
Pharvaris Reports Positive Phase 3 CHAPTER-3 Results For Deucrictibant XR In HAE Prophylaxis
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Pharvaris announced positive topline results from its pivotal Phase 3 CHAPTER-3 trial of deucrictibant extended-release tablets for prevention of hereditary angioedema attacks. The positive late-stage clinical readout materially supports the drug's development and potential regulatory path, likely benefiting Pharvaris shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
PHVS0.85
More News
- Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
- Here are Friday's biggest analyst calls: Nvidia, SpaceX, CoreWeave, Deckers, Unusual Machines & more
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage